10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2021 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2021 10-K (Filed: Feb 7, 2022) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2021 | Dec 31, 2020 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 2,885,600 | 2,193,700 |
| Marketable securities | 2,809,100 | 1,393,300 |
| Accounts receivable, net | 6,036,500 | 4,114,700 |
| Inventories | 1,951,300 | 1,916,600 |
| Prepaid expenses and other current assets | 332,400 | 160,800 |
| Total current assets | 14,014,900 | 9,779,100 |
| Marketable securities | 6,838,000 | 3,135,600 |
| Property, plant, and equipment, net | 3,482,200 | 3,221,600 |
| Deferred tax assets | 876,900 | 858,900 |
| Other noncurrent assets | 222,800 | 168,100 |
| Total assets | 25,434,800 | 17,163,300 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 564,000 | 475,500 |
| Accrued expenses and other current liabilities | 2,206,800 | 1,644,200 |
| Finance lease liabilities | 719,700 | 0 |
| Deferred revenue | 442,000 | 577,700 |
| Total current liabilities | 3,932,500 | 2,697,400 |
| Long-term debt | 1,980,000 | 1,978,500 |
| Finance lease liabilities | 0 | 717,200 |
| Deferred revenue | 73,300 | 57,800 |
| Other noncurrent liabilities | 680,200 | 687,100 |
| Total liabilities | 6,666,000 | 6,138,000 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none | 0 | 0 |
| Additional paid-in capital | 8,087,500 | 6,716,200 |
| Retained earnings | 18,968,300 | 10,893,000 |
| Accumulated other comprehensive (loss) income | (26,200) | 29,300 |
| Treasury Stock, at cost; 19,392,961 shares in 2021 and 16,431,520 shares in 2020 | (8,260,900) | (6,613,300) |
| Total stockholders' equity | 18,768,800 | 11,025,300 |
| Total liabilities and stockholders' equity | 25,434,800 | 17,163,300 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 0 | 0 |
| Common Stock | ||
| Common stock | 100 | 100 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |